Many like to end the year with a bang, and this seems to be the case even in the world of clinical trials. December's select list of trial launches, as recorded by Meddevicetracker, highlighted a number of studies expecting to enroll patients in the hundreds and the thousands.
Among these is Boston Scientific's 1,800-patient US IDE study, MADIT-ICD, to assess whether patients with prior myocardial infarction, diabetes and a relatively preserved ejection fraction of 36-50% would benefit from...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?